РЕМЕДИУМРЕМЕДИУМ1561-59362658-3534Joint-Stock Company Chicot167910.32687/1561-5936-2024-28-1-57-64Original ArticleНекоторые аспекты истории развития эпидемий и пандемийМотыгуллинаЛейсан Илгизовнаmleisi20@mail.ruТухбатуллинаРузалия Габдулхаковнаruzaliya.tukhbatullina@kazangmu.ruКазанский государственный медицинский университет, Казань, Россия151220241576415102025Copyright © 2024, АО "Шико"2024Представлен обзор литературы, который отражает историю развития эпидемий и пандемий с античных времён до наших дней. Отмечены первые исторические упоминания об острых респираторных вирусных инфекциях, проанализированы научные источники, сообщающие о разработке лекарств и вакцин.epidemicspandemicsacute respiratory viral infectionscoronavirus infectionreviewэпидемиипандемииострые респираторные вирусные инфекциикоронавирусная инфекцияобзор1.Briko N. I. Theoretical generalizations in epidemiology: from history to the present. Epidemiology and Vaccinal Prevention. 2018;17(5):5—16.2.Barbieva E. B. Optimization of pharmaceutical counseling for patients with infectious and inflammatory diseases of the upper respiratory tract and ENT organs. Izvestiya vuzov Kyrgyzstana. 2022;(6):46—51.3.Shirokova I., Prozherina Yu. In the battle against viruses. Remedium. 2021;(1):46—49.4.Timchenko V. N., Malinovskaya V. V., Barakina E. V. et al. The role of early etiological interpretation of acute respiratory viral infections in the choice of antiviral therapy in children in hospital settings. Pediatriya im. G. N. Speranskogo. 2020;99(1):100—106.5.Narkevich I. A., Nemyatykh O. D., Kuldyrkaeva E. V. Pharmacovigilance system: international experience and prospects in Russia. Farmatsiya. 2016;65(7):3—7.6.Kupchenko A. N., Ponezheva Zh.B. Modern principles of diagnosis and treatment of acute respiratory viral infections. Arkhiv vnutrenney meditsiny. 2016;6(1):6—12.7.Pappas G., Kiriaze I. J., Falagas M. E. Insights into infectious disease in the era of Hippocrates. Int. J. Infect. Dis. 2008;12(4):347—350.8.Blokhin A. A. New and recurring cross-border infections in human life. Puti k miru i bezopasnosti. 2020;59(2):9—26.9.Simonyan R. Z. The history of medicine: from ancient times to the present. Cheboksary; 2020.10.Potter C. W. A history of influenza. J. Appl. Microbiol. 2001;91(4):572—579.11.Farkhutdinova L. M. From the history of the study of infectious diseases. Arkhiv vnutrenney meditsiny. 2021;11(6):416—423.12.Orlov A. G., Lipin A. N., Kozlov K. L. Treatment of chronic wounds — a look through the centuries. Kubanskiy nauchnyy meditsinskiy zhurnal. 2016;160(5):147—153.13.Mamedov M. K., Kadypova A. A. On the 160th anniversary of the discovery of the cholera vibrio. Cholera and its causative agents are advances in research over a century and a half. Biomeditsina. 2014;(1):23—27.14.Waring J. I. A history of medicine in South Carolina 1960—1970. Charleston; 1971.15.Kholikov I. V. The spread of epidemics, pandemics and mass diseases as a global challenge of our time. Puti k miru i bezopasnosti. 2020;59(2):27—40.16.Gwaltney J. M. Viral respiratory infection therapy: historical perspectives and current trials. Am. J. Med. 2002;112(6A):33S—41S.17.Skvortsov V. V., Orlov O. V. Flu and SARS. Meditsinskaya sestra. 2016;(7):3—6.18.Stanley W. M. The preparation and properties of influenza virus vaccines concentrated and purified by differential centrifugation. J. Exp. Med. 1945;81:193—218.19.Davenport F. M. The search for the ideal influenza vaccine. Postgraduate Med. J. 1979;55:78—86.20.Francis T. Vaccination against influenza. Bull. World Health Org. 1953;8:725—741.21.Parodi V., de Florentiis D., Martini M., Ansaldi F. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging. 2011;28:93—106.22.Barberis I., Martini M., Iavarone F., Orsi A. Available influenza vaccines: immunization strategies, history and new tools for fighting the disease. J. Prevent. Med. Hyg. 2016; 57:E41—E46.23.Francis T., Salk J. E., Pearson H. E., Brown P. N. Protective effect of vaccination against induced influenza A. J. Clin. Invest. 1945;24:536—546.24.Weir J. P., Gruber M. F. An overview of the regulation of influenza vaccines in the United States. Influenza Other Respir. Viruses. 2016;10:354—360.25.Keitel W. A., Neuzil K. M., Treanor J. Immunogenicity, efficacy of inactivated/live virus seasonal and pandemic vaccines. In: Webster R. G. (eds) Textbook of Influenza. Wiley-Blackwell; 2013:311—326.26.Krammer F., Palese P. Advances in the development of influenza virus vaccines. Nature Rev. Drug Discov. 2015;14:167—182.27.Zaman M., Ashraf S., Dreyer N. A., Toovey S. Human infection with avian influenza virus, Pakistan, 2007. Emerg. Infect. Dis. 2011;17:1056—1059.28.Crovari P., Alberti M., Alicino C. History and evolution of influenza vaccines. J. Prevent. Med. Hyg. 2011;52:91—94.29.Shannon I., White C. L., Nayak J. L. Understanding immunity in children vaccinated with live attenuated influenza vaccine, USA. J. Pediatr. Infect. Dis. Soc. 2020:9(Suppl 1):10—14.30.Falsey A. R., Treanor J. J., Tornieporth N. et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J. Infect. Dis. 2009;200:172—180.31.Tisa V., Barberis I., Faccio V. et al. Quadrivalent influenza vaccine: a new opportunity to re-duce the in-fluenza burden. J. Prevent. Med. Hyg. 2016;57:28—33.32.Wille M., Holmes E. C. The ecology and evolution of influenza viruses. Cold Spring Harbor Persp. Med. 2020;10:a038489.33.Lyons, D.M.; Lauring, A. S. Mutation and epistasis in influenza virus evolution. Viruses. 2018;10:407.34.Jiang D., Wang Q., Bai Z. et al. Could environment affect the mutation of h1n1 influenza virus? Int. J. Environ. Res. Public Health. 2020;17:3092.35.Yen H. L. Current and novel antiviral strategies for influenza infection. Curr. Opin. Virol. 2016;18:126—134.36.Bassetti M., Castaldo N., Carnelutti A. Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. Exp. Opin. Pharmacother.2019;20(14):1711—1718.37.Tarbet E. B., Hamilton S., Vollmer A. H. et al. A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses. J. Antimicrob. Chemother. 2014;69(8):2164—2174.38.Vorobjev Y. N. An effective molecular blocker of ion channel of M2 protein as anti-influenza a drug. J. Biomolec. Struct. Dynamics. 2021;39(7):2352—2363.39.Katunina E. A. Amantadine in the treatment of Parkinson’s disease. New opportunities in the context of COVID-19. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova. 2021;121(4):101—106.40.Marra F., Marra C. A., Stiver H. G. A case for rimantadine to be marketed in Canada for prophylaxis of influenza A virus infection. Canad. Respir. J. 2003;10(7):381—388.41.Renzette N., Caffrey D. R., Zeldovich K. B. et al. Evolution of the influenza A virus genome during development of oseltamivir resistance in vitro. J. Virol. 2014;88(1):272—281.42.Boianelli A., Sharma-Chawla N., Bruder D., Hernandez-Vargas E. A. Oseltamivir PK/PD modeling and simulation to evaluate treatment strategies against influenza-pneumococcus coinfection. Front. Cell. Infect. Microbiol. 2016;14(6):60.43.Takahashi E., Sawabuchi T., Kimoto T. et al. Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice. J. Dairy Sci. 2019;102(11):9559—9569.44.Rossignol J. F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014;110:94—103.45.Belardo G., Cenciarelli O., La Frazia S. et al. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. Antimicrob. Agents Chemother. 2015;59(2):1061—1069.46.Vanderlinden E., Vrancken B., Van Houdt J. et al. Distinct effects of T-705 (Favipiravir) and Ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob. Agents and Chemother. 2016;60(11):6679—6691.47.Furuta Y., Komeno T., Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 2017;93(7):449—463.48.Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther. 2020;209:107512.49.Wang C., Horby P. W., Hayden F. G., Gao G. F. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470—473.50.Shchelkanov M. Yu., Popova A. Yu., Dedkov V. G. et al. The history of the study and modern classification of coronaviruses (Nidovirales: Coronaviridae). Infektsiya i immunitet. 2020;10(2):221—246.51.Almatova A. M., Radzhabova M. D., Kavrakov T. D., Sharipov Z. A. Features of the clinical manifestation of COVID-19 infection in the practice of a family doctor. Goals and ways of sustainable economic development. 2021;197—202.52.Umakanthan S., Sahu P., Ranade A. V. et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgraduate Med. J. 2020;96(1142):753—758.53.Sharma A., Ahmad Farouk I., Lal S. K. COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention. Viruses. 2021;13(2):202.54.Romanov B. K. Coronavirus infection COVID-2019. Bezopasnost' i risk farmakoterapii. 2020;8(1):3—8.